Suominen reports Q4 results on Jan 29. FY’26 should see better earnings, yet growth may still be har...
Redeye leaves a comment following OncoZenge’s announcement of a SEK5m bridge financing via a convert...
* Mild winter in Q4, but sequentially easing comps: organic growth -1% * Cost savings took effect in...
* AI should drive data storage demand, but RAM prices are an issue * Small reductions to estimates, ...
Redeye provides commentary on NextCell following the announcement of a SEK15m directed issue and a s...
* Q4e sales SEK 22m (21m), EBIT adj. SEK -5.5m (-6.
Redeye initiates coverage of Coffee Stain Group, a Swedish game development company recognised for i...
Fiskars has been suffering from weak consumer demand for the past three years.
Redeye comments on Avensia’s December sales figures.
Redeyes shares its preview of Xvivo’s Q4 2025 results, due on January 27.
Prostatypes USA-studie har nyligen presenterats i en vetenskaplig tidskrift.
Redeye provides its initial take on VEF’s Q4 2025 report, which featured continued NAV growth and re...
Cicor is an electronics manufacturing services (EMS) company with ~60 years of history, and we view ...
We expect Q4/25 to conclude a year of successful exits, putting VNV in a net cash position but with ...
Redeye gives an initial take on the news that IRLAB has entered into a collaboration with Biomia reg...
* Rottneros Q4 EBITDA of SEK -180m vs. our SEK -80m * Challenging markets for Rottneros and Arctic P...
* Q4'25 numbers due on 10 February at 07:45 CET * Expect new targets on the reporting day, more info...
Warm weather and the efficiency improvement programme should support profitability in Q4/25, we beli...
This morning SyntheticMR announced preliminary Q4 figures amid the ongoing rights issue.
* We forecast -3% EBITA growth in Q4'25 on a tough comp * 8% EBITA growth shows resilience in tough ...
